Introduction {#jhbp673-sec-0005}
============

Hepatectomy is the standard treatment for both benign and malignant diseases of the liver with adequate functional reserve [1](#jhbp673-bib-0001){ref-type="ref"}, [2](#jhbp673-bib-0002){ref-type="ref"}. The mortality rate of hepatectomy is very low in high‐volume centers [2](#jhbp673-bib-0002){ref-type="ref"}, [3](#jhbp673-bib-0003){ref-type="ref"}, [4](#jhbp673-bib-0004){ref-type="ref"}. Despite technical advances, improvements in perioperative management, a greater understanding of the physiology of the liver, and accumulation of experience with liver resection at specialized centers, the postoperative morbidity rate is still relatively high at up to 40% according to previous reports [3](#jhbp673-bib-0003){ref-type="ref"}, [5](#jhbp673-bib-0005){ref-type="ref"}. Major hepatectomy is a complex surgical procedure and has a higher complication rate than minor surgery [5](#jhbp673-bib-0005){ref-type="ref"}, [6](#jhbp673-bib-0006){ref-type="ref"}. Although no consensus has been reached regarding the definition of major hepatectomy, the removal of more than three liver segments is the definition generally accepted worldwide [6](#jhbp673-bib-0006){ref-type="ref"}, [7](#jhbp673-bib-0007){ref-type="ref"}.

Surgical site infection (SSI) is a common complication following hepatectomy and is classified as superficial SSI, deep or incisional SSI, and organ/space SSI [8](#jhbp673-bib-0008){ref-type="ref"}. Organ/space SSI and intra‐abdominal infection (IAI) are lethal complications following hepatectomy, and previous studies have shown that the incidence of IAI following hepatectomy may reach 17% [9](#jhbp673-bib-0009){ref-type="ref"}, [10](#jhbp673-bib-0010){ref-type="ref"}, [11](#jhbp673-bib-0011){ref-type="ref"}, [12](#jhbp673-bib-0012){ref-type="ref"}. IAI is associated with poor long‐term outcomes in patients with both primary and secondary malignancies following hepatectomy [13](#jhbp673-bib-0013){ref-type="ref"}, [14](#jhbp673-bib-0014){ref-type="ref"}, [15](#jhbp673-bib-0015){ref-type="ref"}. Various preoperative and perioperative factors are associated with IAI following hepatectomy. Preoperative risk factors for IAI include the body mass index, serum albumin level, smoking, dialysis, serum bilirubin level, anemia, and repeat hepatectomy. The operative duration, extent of surgery, bile leakage, concomitant bowel surgery, and blood loss are perioperative risk factors for IAI [12](#jhbp673-bib-0012){ref-type="ref"}. The extent of hepatic resection is strongly associated with the development of IAI. Kenjo et al. [2](#jhbp673-bib-0002){ref-type="ref"} and Dokmak et al. [3](#jhbp673-bib-0003){ref-type="ref"} reported higher morbidity rates in patients undergoing major hepatectomy than minor hepatectomy.

The preoperative serum albumin level is strongly associated with outcomes following various types of gastrointestinal surgery, including gastric, pancreatic, and colorectal surgery [16](#jhbp673-bib-0016){ref-type="ref"}, [17](#jhbp673-bib-0017){ref-type="ref"}, as well as non‐gastrointestinal surgery [18](#jhbp673-bib-0018){ref-type="ref"}. The association between serum albumin and IAI is controversial [2](#jhbp673-bib-0002){ref-type="ref"}, [11](#jhbp673-bib-0011){ref-type="ref"}, [12](#jhbp673-bib-0012){ref-type="ref"}. To the best of our knowledge, no study has yet been performed to evaluate the association of the preoperative serum albumin level with IAI in patients undergoing major hepatectomy. The present study was performed to investigate perioperative factors and determine whether the preoperative serum albumin level is associated with IAI following major hepatectomy.

Methods {#jhbp673-sec-0006}
=======

A total of 268 consecutive patients underwent major hepatectomy at the Department of Surgery, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand from January 2008 to December 2018, and their data were retrospectively analyzed. The study protocol was approved by the Institutional Ethical Committee at Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand (protocol number, MURA2019/80). Major hepatectomy was defined as removal of four or more segments. The liver segments were defined according to the Brisbane classification [19](#jhbp673-bib-0019){ref-type="ref"}. All patients underwent preoperative cross‐sectional dynamic imaging using either triple‐phase computed tomography or magnetic resonance imaging. Routine blood examinations included a complete blood count, coagulogram, liver and kidney function tests, and the preoperative serum alpha‐fetoprotein level. The low serum albumin was defined as serum albumin level \<35 g/l. Preoperative characteristics including the American Society of Anesthesiologists (ASA) class, evidence of hepatitis virus B or C, and smoking were recorded. The preoperative nutritional status was assessed from the Nutritional Alert Form (NAF). The patients were classified to A (normal‐mild malnutrition), B (moderate malnutrition), C (severe malnutrition) [20](#jhbp673-bib-0020){ref-type="ref"}. Preoperative indocyanine green retention test at 15 min (ICG‐R15) was also performed. Preoperative biliary intervention was defined as the performance of preoperative percutaneous biliary drainage, endoscopic biliary drainage, and previous operative procedures involving the biliary tract. The indication for preoperative biliary intervention is cholangitis and for preoperative biliary drainage in the patients who had perihilar obstruction. Makuuchi's criteria are used to select patients for curative resection in our center [21](#jhbp673-bib-0021){ref-type="ref"}. The extent of liver resection was based on the patient's liver functional reserve as assessed mainly by Makuuchi's criteria, including the preoperative ascites volume, Child--Pugh score, ICG‐R15 value, and occasionally, volumetric computed tomography analysis. A preoperative evaluation was conducted by a multidisciplinary team including a surgeon, gastroenterologist, medical oncologist, and interventionist every week at our hospital. The platelet‐to‐lymphocyte ratio (PLR), prognostic nutritional index (PNI) and neutrophil‐to‐lymphocyte ratio (NLR) are among the preoperative serum inflammatory indices included in the study. PLR was calculated as the platelet count divided by the lymphocyte count. PNI was calculated as albumin (g/l) + 0.005 × total lymphocyte count (/µl). NLR was calculated as neutrophil count divided by the lymphocyte count.

Perioperative method {#jhbp673-sec-0007}
--------------------

Prophylactic antibiotics were routinely given with intravenous cefazolin or cefoxitin 1.0 g within 30 min before skin incision. The incision type depended on the surgeon's preference. The Pringle maneuver was performed using intermittent clamping. Intraoperative ultrasound was routinely used to stage the disease and to guide parenchymal transection, which was performed using a Cavitron ultrasonic aspirator, the clamp--crushing technique, or a combined technique depending on the surgeon's preference. A prophylactic drainage tube was routinely placed. The suture material was also dependent upon the surgeon's preference. Blood loss was estimated by an anesthesiologist, who also assessed the need for blood transfusion. The operative time was defined as the period from the start of the incision to closure of the abdominal wound.

Postoperative complications {#jhbp673-sec-0008}
---------------------------

Intra‐abdominal infection was defined as an infection that occurred within 30 days postoperatively, appeared to be related to the operation and involved any part of the anatomy other than the incision that was opened or manipulated during the operation, and showed at least one of the following characteristics: purulent drainage from the tube placed through a stab wound into the organ space; isolation of organisms from an aseptically obtained culture of fluid or tissue from the organ space; development of an abscess or other evidence of infection involving the organ space as found on direct examination, during reoperation, or by histopathologic or radiologic examination; or diagnosis of an organ/space SSI made by the surgeon or attending doctor [8](#jhbp673-bib-0008){ref-type="ref"}. Bile leakage was classified as grade A, B, and C according to the International Study Group of Liver Surgery [22](#jhbp673-bib-0022){ref-type="ref"}. The drainage tube was removed after postoperative day 3. The patients who had bile leakage, the drainage tube was placed until there was no evidence of bile leakage. The IAI patients who had sepsis, the reoperation was performed. Postoperative mortality was recorded as 90‐day mortality and in‐hospital mortality.

Statistical analyses {#jhbp673-sec-0009}
--------------------

Among the patient characteristics, continuous variables were compared by Student's *t*‐test and categorical variables were compared by the χ^2^ test or Fisher's exact test. A *P*‐value of \<0.05 was considered statistically significant. The potential risk factors were analyzed by univariate and multivariate methods using a logistic regression model. Independent risk factors were expressed as odds ratio (OR) with 95% confidence interval (CI). The performance of the predictor for the variable factor was analyzed by the receiver operating characteristic (ROC) curves.

Internal validity of the final model's performance in terms of area under the curve (AUC) of the ROC curve was assessed using the bootstrap cross‐validation method. Consequently, the data were resampled with replacement, and for each resample a logistic regression model with the same risk factor as the final model (assuming the final model to be true) was developed. This method was applied to the full, non‐resampled data set to obtain a validating AUC value. This method was repeated 10,000 times (10,000 replicates). The width of the 95% range of the validating AUCs of the resamples (2.5% and 97.5% quantiles for AUCs) was used as the internal validity measure.

Results {#jhbp673-sec-0010}
=======

Patient characteristics and perioperative data {#jhbp673-sec-0011}
----------------------------------------------

A total of 268 patients underwent major hepatectomy from January 2008 to December 2018, of whom 38 (14.6%) had IAI. The overall mortality rate was 4.85% (13/268). For the analyses, the patients were divided into two groups: IAI (*n* = 38) and non‐IAI (*n* = 230). The clinicopathological characteristics of the two groups are shown in Table [1](#jhbp673-tbl-0001){ref-type="table"}. The IAI group contained more patients with a higher ASA class (class IV) (16.22% vs. 4.82%, *P* = 0.034), more patients who had undergone previous biliary intervention (34.11% vs. 12.17%, *P* \< 0.001), a greater aspartate aminotransferase level (57 vs. 36.5 U/l, *P* = 0.003), a longer operative duration (512 vs. 395 min, *P* \< 0.001), greater blood loss (1,800 vs. 1,000 ml, *P* \< 0.001), and a greater length of hospital stay (LOH) (24 vs. 11 days, *P* \< 0.001) than the non‐IAI group. The IAI group also had a lower hemoglobin level (12.1 vs. 12.9 g/dl, *P* = 0.015) and serum albumin level (33.1 vs. 37.7 g/l, *P* \< 0.001) than the non‐IAI group. The IAI group had higher rates of reoperation (13.16% vs. 0.44%, *P *\< 0.001), readmission (15.79% vs. 0.87%, *P* \< 0.001), and mortality (15.79% vs. 3.04%, *P* = 0.001).

###### 

Patients' perioperative characteristics

  Data                                           Total (*n* = 268)         Non‐IAI (*n* = 230)      IAI (*n* = 38)           *P*‐value
  ---------------------------------------------- ------------------------- ------------------------ ------------------------ -----------
  Sex                                                                                                                        
  Male                                           156 (58.21)               135 (58.70)              21 (55.26)               0.691
  Female                                         112 (41.79)               95 (41.30)               17 (44.74)               
  Age, years                                     54.82 ± 12.61             54.42 ± 12.96            57.28 ± 10.08            0.194
  BMI (kg/m^2^), mean ± SD                       23.82 ± 3.69              23.84 ± 3.64             23.67 ± 4.08             0.798
  Comorbidities                                                                                                              
  DM                                             59 (22.01)                49 (21.30)               10 (26.32)               0.490
  Hypertension                                   97 (36.19)                82 (35.65)               15 (39.47)               0.650
  Dyslipidemia                                   33 (12.31)                28 (12.17)               5 (13.16)                0.864
  CKD                                            2 (0.75)                  2 (0.87)                 0                        0.999
  Viral hepatitis                                63 (23.51)                55 (23.91)               8 (21.05)                0.700
  COPD                                           6 (2.24)                  6 (2.61)                 0                        0.314
  Cirrhosis                                      10 (3.73)                 8 (3.48)                 2 (5.26)                 0.591
  ASA class, *n* = 265                                                                                                       
  I                                              25 (9.43)                 24 (10.53)               1 (2.70)                 0.034
  II                                             98 (36.98)                84 (36.84)               14 (37.84)               
  III                                            125 (47.17)               109 (47.81)              16 (43.24)               
  IV                                             17 (6.42)                 11 (4.82)                6 (16.22)                
  Smoking                                        99 (36.94)                85 (36.96)               14 (36.84)               0.989
  Cholangitis                                    6 (2.24)                  6 (2.61)                 0                        0.599
  Previous biliary intervention                  41 (15.30)                28 (12.17)               13 (34.11)               0.000
  Platelet count ×10^3^, *n* = 265               248 (87, 703)             244 (87, 669)            284 (108, 703)           0.168
  Hb, g/dl, *n* = 261                            12.8 (5.7, 40.9)          12.9 (5.7, 40.9)         12.1 (7.9, 15.1)         0.015
  BUN, mg/dl, *n* = 256                          12 (4, 43)                12 (4, 43)               13 (8, 40)               0.245
  AST, U/l, *n* = 254                            37 (8, 378)               36.5 (8, 378)            57 (10, 220)             0.003
  ALT, U/l, *n* = 253                            43 (10, 229)              41 (10, 229)             58.5 (13, 221)           0.000
  Cholesterol, mg/dl, *n* = 210                  199.30 ± 48.85            203.02 ± 49.67           174.46 ± 44.34           0.004
  eGFR, *n* = 258                                91.53 (4.55, 133.50)      92.05 (4.55, 133.5)      80.00 (30.34, 129.96)    0.077
  PT, *n* = 239                                  12.10 (9.70, 27.00)       12.00 (9.70, 27.00)      12.90 (10.00, 18.10)     0.015
  TB, mg/dl, *n* = 242                           0.6 (0.2, 24.7)           0.6 (0.2, 24.7)          0.7 (0.2, 5.1)           0.293
  PNI, *n* = 214                                 93.78 ± 34.36             94.34 ± 34.85            90.50 ± 31.65            0.566
  PLR, *n* = 217                                 140..35 (49.49, 625.07)   137.75 (49.49, 587.32)   155.26 (63.98, 625.07)   0.222
  NLR, *n* = 217                                 2.14 (0.57, 30.66)        2.14 (0.57, 30.67)       2.46 (0.80, 21.5)        0.376
  Albumin, g/l, *n* = 261                        37.2 (21.7, 49)           37.7 (22.2, 49)          33.1 (21.7, 45.7)        0.000
  ≥35                                            173 (66.28)               156 (69.64)              17 (45.95)               0.005
  \<35                                           88 (33.72)                68 (30.36)               20 (54.05)               
  ICG‐R15, *n* = 110                             11.40 (0.1, 53.8)         11.3 (0.1, 53.8)         11.9 (1.9, 36.6)         0.416
  NAF score, *n* = 267                                                                                                       
  A (normal‐mild malnutrition)                   192 (71.91)               167 (72.93)              25 (65.79)               0.365
  B (moderate malnutrition)                      75 (28.09)                62 (27.07)               13 (34.21)               
  Diagnosis                                                                                                                  
  Hepatocellular carcinoma                       84 (31.34)                73 (31.74)               11 (28.95)               0.144
  Cholangiocarcinoma                             89 (33.21)                69 (30.00)               20 (52.63)               
  Liver metastasis                               50 (18.66)                45 (19.57)               5 (13.16)                
  Hepatolithiasis                                3 (1.12)                  2 (0.87)                 1 (2.63)                 
  Liver abscess                                  1 (0.37)                  1 (0.43)                 0                        
  Liver donor                                    22 (8.21)                 22 (9.57)                0                        
  Benign hepatic tumor                           10 (3.73)                 9 (3.91)                 1 (2.63)                 
  Gallbladder cancer                             1 (0.37)                  1 (0.43)                 0                        
  Hepatic cyst                                   8 (2.99)                  8 (3.48)                 0                        
  Biliary reconstruction, *n* = 265              4 (1.51)                  3 (1.32)                 1 (2.63)                 0.464
  Operative time, min                            411.30 ± 150.69           395.16 ± 145.78          512.63 ± 143.09          0.000
  Blood loss, ml                                 1,200 (50, 32,000)        1,000 (50, 3,200)        1,800 (300, 16,000)      0.000
  Antibiotic coated suture material, *n* = 220                                                                               
  Antibiotic coated                              206 (93.64)               178 (93.19)              28 (96.55)               0.700
  Non‐antibiotic coated                          14 (6.36)                 13 (6.81)                1 (3.45)                 
  Closure suture material, *n* = 219                                                                                         
  Monofilament                                   96 (43.84)                79 (41.36)               17 (60.71)               0.054
  Multifilament                                  123 (56.16)               112 (58.64)              11 (39.29)               
  Bile leakage                                                                                                               
  No                                             235 (87.69)               205 (89.13)              30 (78.95)               0.077
  Yes                                            33 (12.31)                25 (10.87)               8 (21.05)                
  Treatment, *n* = 267                                                                                                       
  Stitch off                                     7 (2.62)                  5 (2.18)                 2 (5.26)                 0.271
  PCD                                            18 (6.74)                 5 (2.18)                 13 (34.21)               0.000
  Reoperation                                    6 (2.25)                  1 (0.44)                 5 (13.16)                0.000
  LOH, days                                      11 (3, 106)               11 (3, 106)              24.5 (7, 90)             0.000
  Readmission                                    8 (2.99)                  2 (0.87)                 6 (15.79)                0.000
  Death                                          13 (4.85)                 7 (3.04)                 6 (15.79)                0.001

Data are presented as *n* (%), mean ± standard deviation, or median (range)

*ALT* alanine aminotransferase, *ASA* American Society of Anesthesiologists, *AST* aspartate aminotransferase, *BMI* body mass index, *BUN* blood urea nitrogen, *COPD* chronic obstructive pulmonary disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *Hb* hemoglobin, *IAI* intra‐abdominal infection, *ICG‐R15* indocyanine green retention test at 15 min, *LOH* length of hospital stay, *NAF* nutritional alert form, *NLR* neutrophil‐to‐lymphocyte ratio, *PCD* percutaneous drainage, *PLR* platelet‐to‐lymphocyte ratio, *PNI* prognostic nutritional index, *PT* prothrombin time, *TB* total bilirubin
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Regarding to the preoperative serum albumin, the preoperative characteristics of patients associated with normal and low serum albumin level are displayed in Table [2](#jhbp673-tbl-0002){ref-type="table"}. The low serum albumin group contained more patients with higher ASA class (class IV) (12.6 vs. 3.47%, *P* \< 0.001), higher smoking populations (47.7 vs. 32.9%, *P* = 0.020), more patients who had undergone previous biliary intervention (29.5 vs. 8.09%, *P* \< 0.001), higher platelet level (294 vs. 234 × 10^3^, *P* \< 0.001), higher aspartate aminotransferase level (42.5 vs. 34.5, *P* = 0.001), longer prothrombin time (12.8 vs. 11.8, *P* \< 0.001), higher serum total bilirubin level (1.07 vs. 1.02 mg/dl, *P* = 0.008), greater malignant patients (86.3 vs. 72.2%, *P* = 0.010) than normal serum albumin group. The low serum albumin group also had lower hemoglobin level (11.8 vs. 13.1 g/dl, *P* \< 0.001).

###### 

Patients' perioperative characteristics compared between normal and low serum albumin groups

  Data                                           Total (*n* = 261)        Albumin ≥35 (*n* = 173)   Albumin \<35 (*n* = 88)   *P*‐value
  ---------------------------------------------- ------------------------ ------------------------- ------------------------- -----------
  Sex                                                                                                                         
  Male                                           153 (58.62)              95 (54.91)                58 (65.91)                0.088
  Female                                         108 (41.38)              78 (45.09)                30 (34.09)                
  Age, years                                     55.01 ± 12.42            54.26 ± 13.18             56.46 ± 10.70             0.148
  BMI                                            23.8 ± 3.68              23.92 ± 3.47              23.76 ± 4.11              0.746
  Comorbidities                                                                                                               
  DM                                             59 (22.61)               36 (20.81)                23 (26.14)                0.331
  Hypertension                                   96 (36.78)               62 (35.84)                34 (38.64)                0.658
  Dyslipidemia                                   32 (12.26)               21 (12.14)                11 (12.50)                0.933
  Chronic kidney disease                         2 (0.77)                 2 (1.16)                  0                         0.551
  Viral hepatitis                                61 (23.37)               41 (23.70)                20 (22.73)                0.861
  COPD                                           5 (1.92)                 3 (1.73)                  2 (2.27)                  0.764
  Cirrhosis                                      10 (3.83)                7 (4.05)                  3 (3.41)                  0.800
  ASA class, *n* = 260                                                                                                        
  I                                              24 (9.23)                23 (13.29)                1 (1.15)                  0.000
  II                                             95 (36.54)               72 (41.62)                23 (26.44)                
  III                                            124 (48.69)              72 (41.62)                52 (59.77)                
  IV                                             17 (6.54)                6 (3.47)                  11 (12.64)                
  Smoking                                        99 (37.93)               57 (32.95)                42 (47.73)                0.020
  Cholangitis                                    6 (2.30)                 3 (1.73)                  3 (3.41)                  0.408
  Previous biliary intervention                  40 (15.33)               14 (8.09)                 26 (29.55)                0.000
  Platelet count ×10^3^, *n* = 260               247 (87, 703)            234 (102, 630)            294 (87, 703)             0.000
  Hb, g/dl, *n* = 257                            12.8 (5.7, 40.9)         13.1 (5.7, 40.9)          11.8 (7.9, 40.9)          0.000
  BUN, mg/dl, *n* = 252                          12 (4, 43)               13 (4, 43)                12 (5, 34.8)              0.147
  AST, U/l, *n* = 260                            37 (8, 378)              34.5 (8, 378)             42.5 (10, 235)            0.001
  ALT, U/l, *n* = 259                            43 (10, 229)             41 (12, 229)              50 (10, 224)              0.105
  Cholesterol, mg/dl, *n* = 215                  199.19 ± 49.97           202.90 ± 50.52            191.91 ± 48.39            0.132
  eGFR, *n* = 258                                91.04 (4.55, 133.5)      91.61 (4.55, 133.50)      89.49 (33.60, 129.96)     0.992
  PT, *n* = 239                                  12.10 (9.70, 27.00)      11.8 (9.70, 27.00)        12.80 (10.80, 26.1)       0.000
  TB, mg/dl, *n* = 241                           0.6 (0.2, 21.4)          0.6 (0.2, 12)             0.7 (0.2, 21.4)           0.008
  PNI, *n* = 214                                 93.78 ± 34.36            96.27 ± 33.84             88.56 ± 35.11             0.125
  PLR, *n* = 214                                 140.23 (49.49, 625.07)   128.06 (54.55, 587.32)    176.69 (49.49, 625.07)    0.000
  NLR, *n* = 214                                 2.15 (0.57, 30.67)       1.96 (0.57, 30.67)        2.62 (0.84, 21.50)        0.001
  IAI                                                                                                                         
  No                                             224 (85.82)              156 (90.17)               68 (77.27)                0.005
  Yes                                            37 (14.18)               17 (9.83)                 20 (22.73)                
  ICG‐R15, *n* = 110                             11.4 (0.1, 53.8)         11.3 (0.1, 29.5)          12.2 (0.1, 53.8)          0.811
  NAF score, *n* = 261                                                                                                        
  A (normal‐mild malnutrition)                   186 (71.26)              129 (74.57)               57 (64.77)                0.098
  B (moderate malnutrition)                      75 (28.74)               44 (25.43)                31 (35.23)                
  Diagnosis                                                                                                                   
  Hepatocellular carcinoma                       82 (31.42)               51 (29.48)                31 (35.23)                0.015
  Cholangiocarcinoma                             87 (33.33)               50 (28.90)                37 (42.05)                 
  Liver metastasis                               50 (19.16)               35 (20.23)                15 (17.05)                 
  Hepatolithiasis                                3 (1.15)                 2 (1.16)                  1 (1.14)                   
  Liver abscess                                  1 (0.38)                 0                         1 (1.14)                   
  Liver donor                                    20 (7.66)                19 (10.98)                1 (1.14)                   
  Benign hepatic tumor                           10 (3.83)                9 (5.20)                  1 (1.14)                   
  Gallbladder cancer                             --                       --                        --                        --
  Hepatic cyst                                   8 (3.07)                 7 (4.05)                  1 (1.14)                   
  Biliary reconstruction, *n* = 260              4 (1.54)                 4 (2.33)                  0                         0.303
  Operative time, min                            411.78 ± 152.03          382.94 ± 136.75           469.13 ± 1164.94          0.000
  Blood loss, ml                                 1,200 (50, 32,000)       1,000 (50, 16,000)        1,600 (100, 32,000)       0.000
  Antibiotic coated suture material, *n* = 217                                                                                
  Antibiotic coated                              203 (93.55)              137 (94.48)               66 (91.67)                0.427
  Non‐antibiotic coated                          14 (6.45)                8 (5.52)                  6 (8.33)                  
  Closure suture material, *n* = 216                                                                                          
  Monofilament                                   94 (43.52)               60 (41.38)                34 (47.89)                0.365
  Multifilament                                  122 (56.48)              85 (58.62)                37 (52.11)                
  Bile leakage                                                                                                                
  No                                             228 (87.36)              150 (86.71)               78 (88.64)                0.657
  Yes                                            33 (12.64)               23 (13.29)                10 (11.36)                 
  Treatment                                                                                                                   
  Stitch off, *n* = 261                          7 (2.68)                 6 (3.47)                  1 (1.14)                  0.270
  PCD, *n* = 261                                 17 (6.51)                11 (6.36)                 6 (6.82)                  0.887
  Reoperation, *n* = 267                         6 (2.30)                 2 (1.16)                  4 (4.55)                  0.194
  LOH, days                                      11 (1, 106)              10 (1, 106)               15 (1, 90)                0.000
  Readmission                                    8 (3.07)                 6 (3.47)                  2 (2.27)                  0.721
  Death                                          12 (4.60)                2 (1.16)                  10 (11.36)                0.000

Data are presented as *n* (%), mean ± standard deviation, or median (range)

*ALT* alanine aminotransferase, *ASA* American Society of Anesthesiologists, *AST* aspartate aminotransferase, *BMI* body mass index, *BUN* blood urea nitrogen, *COPD* chronic obstructive pulmonary disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *Hb* hemoglobin, *IAI* intra‐abdominal infection, *ICG‐R15* indocyanine green retention test at 15 min, *LOH* length of hospital stay, *NAF* nutritional alert form, *NLR* neutrophil to lymphocyte ratio, *PCD* percutaneous drainage, *PLR* platelet‐to‐lymphocyte ratio, *PNI* prognostic nutritional index, *PT* prothrombin time, *TB* total bilirubin
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Analysis of risk factors associated with IAI {#jhbp673-sec-0012}
--------------------------------------------

The results of the univariate and multivariate analyses of potential predictors of IAI are shown in Table [3](#jhbp673-tbl-0003){ref-type="table"}. The univariate analysis identified the following variables as significantly associated with IAI: ASA class IV (OR 13.0; 95% CI 1.40--122.2; *P* \< 0.05), previous biliary intervention (OR 3.75; 95% CI 1.72--8.16; *P* \< 0.01), hemoglobin concentration (OR 0.81; 95% CI 0.67--0.98; *P* \< 0.05), serum albumin concentration (OR 0.887; 95% CI 0.83--0.94; *P* \< 0.01), operative time (OR 1.612; 95% CI 1.28--2.02; *P* \< 0.01), and blood loss (OR 1.153; 95% CI 1.03--1.28; *P* \< 0.01). In the multivariate analysis, only the operative time (OR 1.506; 95% CI 1.18--1.91; *P* \< 0.01) and serum albumin concentration (OR 0.911; 95% CI 0.84--0.97; *P* \< 0.05) were significantly associated with IAI.

###### 

Univariate and multivariate analysis of predictors of intra‐abdominal infection

  Data                                Univariate             Multivariate                        
  ----------------------------------- ---------------------- -------------- -------------------- -------
  Sex                                                                                            
  Male                                1                                                           
  Female                              1.150 (0.57--2.29)     0.691                                
  Age, years                          1.018 (0.99--1.05)     0.195                                
  BMI                                 0.987 (0.89--1.08)     0.798                                
  Comorbidities                                                                                  
  DM                                  1.319 (0.59--2.90)     0.491                                
  Hypertension                        1.177 (0.58--2.38)     0.650                                
  Dyslipidemia                        1.093 (0.39--3.03)     0.864                                
  Chronic kidney disease              --                     --                                   
  Viral hepatitis                     0.848 (0.36--1.95)     0.700                                
  COPD                                --                     --                                   
  Cirrhosis                           1.541 (0.31--7.55)     0.593                                
  ASA class                                                                                      
  I                                   1                                                           
  II                                  4.000 (0.50--31.98)    0.191                                
  III                                 3.522 (0.44--27.86)    0.233                                
  IV                                  13.090 (1.40--122.2)   0.024                                
  Smoking                             0.995 (0.48--2.02)     0.989                                
  Cholangitis                         --                     --                                   
  Previous biliary intervention       3.751 (1.72--8.16)     0.001                                
  Platelet count x10^3^               1.259 (0.92--1.70)     0.136                                
  Hb, g/dl                            0.814 (0.67--0.98)     0.035                                
  BUN, mg/dl                          1.038 (0.97--1.10)     0.201                                
  AST, U/l                            1.006 (0.99--1.02)     0.050                                
  ALT, U/l                            1.009 (1.00--1.02)     0.023                                
  Cholesterol, mg/dl                  0.987 (0.97--0.99)     0.006                                
  eGFR                                0.985 (0.97--1.00)     0.068                                
  PT                                  1.130 (0.96--1.32)     0.124                                
  TB, mg/dl                           0.980 (0.84--1.14)     0.794                                
  PNI                                 0.996 (0.98--1.01)     0.564                                
  PLR                                 1.291 (0.88--1.88)     0.185                                
  NLR                                 1.066 (0.96--1.18)     0.223                                
  Albumin, g/l                        0.887 (0.83--0.94)     0.000          0.910 (0.83--0.99)   0.031
  ICG‐R15                             1.338 (0.91--1.95)     0.134                                
  NAF score                                                                                      
  A                                   1                                                           
  B                                   1.400 (0.67--2.91)     0.366                                
  Preoperative diagnosis                                                                         
  Benign                              1                                                           
  Malignant                           1.828 (0.61--5.46)     0.280                                
  Biliary reconstruction              2.018 (0.20--19.92)    0.548                                
  Operative time, min                 1.612 (1.28--2.02)     0.000          1.580 (1.19--2.09)   0.001
  Blood loss, ml                      1.153 (1.03--1.28)     0.008                                
  Antibiotic coated suture material                                                              
  Antibiotic coated                   1                                                           
  Non‐antibiotic coated               0.489 (0.06--3.88)     0.499                                
  Closure suture material                                                                        
  Monofilament                        1                      0.058                                
  Multifilament                       0.456 (0.20--1.03)                                          
  Bile leakage                                                                                   
  No                                  1                                                           
  Yes                                 2.186 (0.90--5.29)     0.083                                

*ALT* alanine aminotransferase, *ASA* American Society of Anesthesiologists, *AST* aspartate aminotransferase, *BMI* body mass index, *BUN* blood urea nitrogen, *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *Hb* hemoglobin, *IAI* intra‐abdominal infection, *ICG‐R15* indocyanine green retention test at 15 min, *LOH* length of hospital stay, *NAF* nutritional alert form, *NLR* neutrophil to lymphocyte ratio, *OR* odds ratio, *PCD* percutaneous drainage, *PLR* platelet‐to‐lymphocyte ratio, *PNI* prognostic nutritional index, *PT* prothrombin time, *TB* total bilirubin
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Predictors of IAI based on preoperative serum albumin level and operative duration {#jhbp673-sec-0013}
----------------------------------------------------------------------------------

The performance of the final prediction model of important risk factors for IAI was examined in 268 patients. When the final model was fitted using total logistic regression, the operative time and albumin concentration remained in the final model. According to our final prediction model, the predictive performance of the serum albumin level and operative duration for the risk of IAI based on 268 patients was shown by an AUC of 0.7846 (Fig. [1](#jhbp673-fig-0001){ref-type="fig"}a). Moreover, a logistic regression model to estimate the probability of IAI based on preoperative serum albumin and operative duration in the 298 patients was constructed from those risk factors as described in the following formula:$$\text{Predicted}\,\text{probability} = 0.683 + 1.506\left( {\text{operative}\,\text{time}} \right) + 0.911\left( \text{albumin} \right).$$

![(**a**) Receiver operating characteristic curve for predicting intra‐abdominal infection based on the serum albumin level and operative duration. The area under the receiver operating characteristic curve is 0.7846. (**b**) This figure shows a contour plot the estimated probability of intra‐abdominal infection following major hepatectomy stratified according to the serum albumin concentration and operative duration, based on the logistic regression model. As an example, the darkest blue shaded are in the upper left had corner of the figure represents probabilities of intra‐abdominal infection between 0.6--0.8, in which the operative duration ranges between 450--900 min, and the preoperative albumin level ranges between 22--32 g/l](JHBP-26-479-g001){#jhbp673-fig-0001}

The performance of the final model for the probability of IAI in 268 patients in terms of the AUC showed the AUC to be 0.785, standard error, 0.035 (Fig. [1](#jhbp673-fig-0001){ref-type="fig"}). Calculations for the Bootstrap cross‐validation showed the 2.5--97.5% quantiles (95%) interval of the 10,000 resamples to be between 0.741 and 0.787, which included the AUC of the full data (0.785). The width of this interval is only 0.046 and can be considered sufficiently narrow (of the same order as the standard error of the AUC estimate), confirming the validity of the final model.

Discussion {#jhbp673-sec-0014}
==========

Major hepatectomy, which is defined as the removal of four or more liver segments, is a complex surgery associated with a high morbidity rate when compared with minor hepatectomy [5](#jhbp673-bib-0005){ref-type="ref"}, [6](#jhbp673-bib-0006){ref-type="ref"}, [7](#jhbp673-bib-0007){ref-type="ref"}, [14](#jhbp673-bib-0014){ref-type="ref"}. Previous studies have demonstrated that postoperative morbidity is associated with an increased LOH, a higher reoperation rate, a subsequently higher cost of the inpatient stay, and poor long‐term outcomes [23](#jhbp673-bib-0023){ref-type="ref"}, [24](#jhbp673-bib-0024){ref-type="ref"}. Our study results are consistent with these previous reports in that the LOH, reoperation rate, and mortality rate were significantly higher in the IAI group. Infectious complications following hepatectomy are common; according to one report, the incidence rate may reach 20% [13](#jhbp673-bib-0013){ref-type="ref"}. A common infectious complication is IAI or organ/space SSI, and the long‐term outcomes are affected by this complication [13](#jhbp673-bib-0013){ref-type="ref"}, [14](#jhbp673-bib-0014){ref-type="ref"}. The mechanisms underlying the poor long‐term outcomes of patients with postoperative IAI are postulated to involve the inflammatory process. Postoperative infections are associated with excessive and sustained levels of proinflammatory cytokine release, and cell‐mediated immunity is suppressed by the effects of anesthesia and the postoperative stress response, which in turn increases the growth of occult micrometastasis [25](#jhbp673-bib-0025){ref-type="ref"}. In the present study, the incidence of IAI following major hepatectomy was 14%, which is comparable with previous studies [10](#jhbp673-bib-0010){ref-type="ref"}, [15](#jhbp673-bib-0015){ref-type="ref"}. However, the incidence of IAI in our study was relatively higher than previous studies from Moreno Elola‐Olaso et al. [11](#jhbp673-bib-0011){ref-type="ref"} and Kenjo et al. [2](#jhbp673-bib-0002){ref-type="ref"}. This may be explained by differences in the patient characteristics and operative time. The preoperative serum albumin in our study was lower (3.7 vs. 4.0 g/dl) and longer operative duration (411 vs. 253 min) than previous two studies. Moreover, patients in our study had a higher proportion of low serum albumin group (33.7 vs. 16%) than previous studies.

From our study, the multivariate analysis showed that the independent factors associated with IAI following major hepatectomy were the preoperative serum albumin level and the operative time. Serum albumin is a negatively charged protein that is synthesized by hepatocytes and released into the circulation, and the rate of albumin synthesis by hepatocytes is regulated by changes in the plasma colloid pressure, the metabolic and inflammatory state of the host, and various anabolic and catabolic hormones [26](#jhbp673-bib-0026){ref-type="ref"}, [27](#jhbp673-bib-0027){ref-type="ref"}. Serum albumin has been used as a surrogate marker of patients' nutritional state worldwide. Fuhrman et al. [27](#jhbp673-bib-0027){ref-type="ref"} reported that inflammation exerts the most significant effects on the serum protein level by altering normal hepatic protein metabolism and inducing capillary leakage. They concluded that hepatic proteins are indicators of morbidity and mortality and recovery from acute and chronic disease. The preoperative serum albumin is strongly associated with postoperative complications in patients undergoing hepatectomy [4](#jhbp673-bib-0004){ref-type="ref"}. However, the association of preoperative hypoalbuminemia as a predictor of postoperative IAI following hepatectomy is controversial. Moreover, most studies have included both minor and major hepatectomy [13](#jhbp673-bib-0013){ref-type="ref"}, [23](#jhbp673-bib-0023){ref-type="ref"}. In the present study, all patients underwent major hepatectomy, which is a complex surgery with a high morbidity rate. Our results showed that the serum albumin level was a significant independent factor associated with IAI. Regarding to the preoperative hypoalbuminemia (\<35 g/l) patients had significantly greater incidence of IAI following major hepatic resection than normal groups. This result is consistent with previous reports from two large cohort studies from the United States. Moreno Elola‐Olaso et al. [11](#jhbp673-bib-0011){ref-type="ref"} performed a large‐population retrospective study of the predictors of SSI after liver resection using the American College of Surgeons National Surgical Quality Improvement Program (ACS‐NSQIP) database, and the results showed that serum albumin was a predictor of SSI (both superficial and deep or organ/space SSI). Neumayer et al. [28](#jhbp673-bib-0028){ref-type="ref"} performed a large‐population study and found that among 163,624 patients undergoing vascular and general surgical procedures, low serum albumin levels of \<3.5 mg/dl was independent risk factors associated with increased risk of SSI. According to these reports, the preoperative serum albumin level is strongly predictive of postoperative IAI following hepatectomy, especially major hepatectomy. Hypoalbuminemia, which is commonly observed in malnutrition patients is associated with a series of physiological derangement that may lead to complications and death [29](#jhbp673-bib-0029){ref-type="ref"}. Consequently, the malnourished patients who are undergoing major operations are at significant risk from perioperative complications such as infectious complications [30](#jhbp673-bib-0030){ref-type="ref"}. The hypoalbuminemia associated with IAI following hepatectomy is explained by alterations in both innate and adaptive immune function contribute significantly to increased susceptibility to infections [31](#jhbp673-bib-0031){ref-type="ref"}. Moreover, protein wasting during the postoperative period is believed to represent the metabolic cost of rapid mobilizing amino acids for wound healing and the synthesis of immune cells and proteins [32](#jhbp673-bib-0032){ref-type="ref"}. The recent guideline from European Society for Clinical Nutrition and Metabolism (ESPEN) state that nutrition is critically important to recovery from major surgery and patients at a high risk due to impaired nutritional status should ideally receive oral supplementation prior to major surgery, even if this results in the delay of resection of a malignancy [33](#jhbp673-bib-0033){ref-type="ref"}. Nevertheless, the serum albumin following preoperative nutritional intervention is not considered as a marker for well‐nourished patients, because of the nutritional support often fails to improve serum albumin levels [29](#jhbp673-bib-0029){ref-type="ref"}. To the best of our knowledge, no randomized, controlled trial study has yet been performed to evaluate the increase of the preoperative serum albumin level with IAI in patients undergoing major hepatectomy. Thus, a further well‐designed prospective randomized controlled trial study comparing low and high serum albumin patients undergoing major hepatectomy should be conducted.

Our study also showed that the operative time was an independent factor associated with IAI following major hepatectomy. A prolonged operative time is associated with an increased risk of postoperative SSI [34](#jhbp673-bib-0034){ref-type="ref"}, [35](#jhbp673-bib-0035){ref-type="ref"}. Procter et al. [34](#jhbp673-bib-0034){ref-type="ref"} performed a retrospective study of 299,359 operations performed at 173 hospitals from the ACS‐NSQIP and found that the infectious complication rate increased linearly with the operative duration. They concluded that the operative duration is independently associated with increased infectious complications and the LOH after adjustment for procedure‐ and patient‐related risk factors [34](#jhbp673-bib-0034){ref-type="ref"}. A prolonged operative time is associated with increased exposure of microbes to the environment, heightened surgical stress to the immune system, and diminished efficacy of antimicrobial prophylaxis over time [13](#jhbp673-bib-0013){ref-type="ref"}, [35](#jhbp673-bib-0035){ref-type="ref"}. Several studies have shown that the operative time is a significant independent factor associated with SSI, including organ/space SSI, in patients undergoing hepatectomy [11](#jhbp673-bib-0011){ref-type="ref"}, [12](#jhbp673-bib-0012){ref-type="ref"}. Determinants of the operative duration are multifactorial and include the operative type, proficiency of the surgeon, presence of surgical trainees, communication among operative professionals, and whether the operation is performed on an emergency basis [36](#jhbp673-bib-0036){ref-type="ref"}. Major hepatectomy usually has a long operative time because of the complexity of the operation. With respect to improvements in the efficacy of the procedure to reduce the operative duration, Procter et al. [34](#jhbp673-bib-0034){ref-type="ref"} and Haynes et al. [37](#jhbp673-bib-0037){ref-type="ref"} recommended improvements in team communication and the consistency of operating room staffing using a surgical safety checklist program, technology, and process efficiency to reduce the operative duration.

This study had some limitations. First, because of its retrospective nature, some selection bias may have been present. Second, the population of our study was relatively small when compared with previous studies.

Conclusion {#jhbp673-sec-0015}
==========

Major hepatectomy is associated with a high morbidity rate. The preoperative serum albumin level is an important marker of patients' nutritional and inflammatory status. The present study indicates that the serum albumin level and operative duration are significant predictors of postoperative IAI. In patients with a low serum albumin level who are undergoing major hepatectomy, the surgeon should consider preoperative nutritional intervention with the use of a short‐term high‐protein supplement diet and closely monitor the patients for the development of postoperative IAI. A further prospective study of perioperative nutritional support to improve treatment outcomes in such patients should be conducted.
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